Teladoc Health (NYSE:TDOC) Stock

TELADOC HEALTH INC

Teladoc Health

Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.

Teladoc Health Inc

B of A Securities analyst Allen Lutz maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $8 to $7.

News

Price Target

Analyst Ratings

TDOC

B of A Securities Maintains Neutral on Teladoc Health, Lowers Price Target to $7

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Teladoc Health and provided 12-month price targets. The average target is $9.43, accompanied by a high estimate of $13.00 and a low estimate of $7.00. This current average has decreased by 16.03% from the previous average price target of $11.23. 
<img src="https://www.benzinga.com/files/images/story/2025/1748368868_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Teladoc Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$9.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Grossman</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$7.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.75</td>
<td>$11.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Teladoc Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Get to Know Teladoc Health Better</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>Teladoc Health's Economic Impact: An Analysis</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3M period, Teladoc Health faced challenges, resulting in a decline of approximately -2.59% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin is impressive, surpassing industry averages. With a net margin of -14.78%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Teladoc Health's ROE excels beyond industry benchmarks, reaching -6.37%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Teladoc Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -2.67%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 1.11, Teladoc Health adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Teladoc Health Stock: Analyst Perspectives (11 Ratings)

Truist Securities analyst Jailendra Singh maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $10 to $9.

Truist Securities Maintains Hold on Teladoc Health, Lowers Price Target to $9

JPMorgan analyst Lisa C. Gill <a href="https://www.benzinga.com/quote/TDOC/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained a Neutral</a> rating on Teladoc Health, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) on Thursday with a price target of $9, down from the prior $11.
On April 30, Teladoc reported <a href="https://www.benzinga.com/general/health-care/25/04/45119362/teladoc-health-stock-slides-on-q1-earnings-as-company-cuts-fy25-guidance" target="_blank" rel="noreferrer noopener">first-quarter revenue</a> of $629.4 million, down 3%, beating the consensus estimate of $619.29 million. The company reported a first-quarter loss of 53 cents per share, missing analyst estimates for a loss of 34 cents per share.
Also Read: <a href="https://www.benzinga.com/general/health-care/25/03/44170605/teladoc-health-partners-with-eli-liilys-lillydirect-to-expand-access-to-zepbound-for-weight-loss" target="_blank" rel="noreferrer noopener">Teladoc Health Partners With Eli Liily&#8217;s LillyDirect to Expand Access to Zepbound For Weight Loss</a>
Teladoc expects second-quarter revenue of $614 million-$633 million and full-year revenue of $2.47 billion-$2.58 billion. Analysts are anticipating full-year revenue of $2.52 billion.
The company also lowered its full-year earnings outlook. Teladoc anticipates a 2025 loss of $0.90-$1.40 per share, down from prior guidance for a loss of $0.50-$1.10 per share. Analysts are forecasting a loss of 93 cents per share.
Following first-quarter earnings, Gill updated her Teladoc model. The analyst&#8217;s fiscal 2025 revenue estimate decreased to $2.516 billion from $2.520 billion prior, and she modeled an adjusted EBITDA of $282 million (down from $294 million prior).
Gill lowered her fiscal 2026 revenue estimate to $2.547 billion from $2.560 billion prior, and her fiscal 2026 adjusted EBITDA estimate moved to $304 million (down from $314 million prior).
Gill established a December 2025 price target of $9, based on an EV/adjusted EBITDA multiple of ~6.5 times her 2026 adjusted EBITDA estimate. The ~6.5 times multiple represents a sizable discount to Teladoc&#8217;s pre-pandemic historical average multiple. 
The analyst pointed to the current challenges and uncertainty in the DTC behavioral health business and an uncertain macroeconomic environment. While she noted that the current valuation for Teladoc reflects much of the uncertainty around BetterHelp, she acknowledged that the current lack of visibility creates a near-term overhang. 
Balanced against these current challenges and uncertainties, Gill pointed to a sizable TAM with a significant runway for growth based on continued virtual care adoption, a leading competitive position, expansion opportunities (including the rollout of the company&#8217;s Primary360 offering), an attractive margin profile, and a strong balance sheet (the company is EBITDA and cash flow positive).
TDOC Price Action: Teladoc shares were up 2.4% at $7.43 at last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/ipos/25/05/45470473/why-is-chinese-lidar-sensor-maker-hesai-stock-trading-higher-on-friday" target="_blank" rel="noreferrer noopener">Why Is Chinese Lidar Sensor Maker Hesai Stock Trading Higher On Friday?</a></li>
</ul>
Photo: Shutterstock

Reiteration

Trading Ideas

Teladoc's Outlook Clouds As JPMorgan Points To Uncertainty In Behavioral Health, Margin Pressure

Wells Fargo analyst Stan Berenshteyn maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Equal-Weight and lowers the price target from $10 to $8.

Wells Fargo Maintains Equal-Weight on Teladoc Health, Lowers Price Target to $8

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $14 to $12.

Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $12

Goldman Sachs analyst David Roman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Buy and lowers the price target from $13 to $10.

Goldman Sachs Maintains Buy on Teladoc Health, Lowers Price Target to $10

Stifel analyst David Grossman maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $9 to $8.

Stifel Maintains Hold on Teladoc Health, Lowers Price Target to $8

Evercore ISI Group analyst Elizabeth Anderson maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a In-Line and lowers the price target from $8 to $7.

Evercore ISI Group Maintains In-Line on Teladoc Health, Lowers Price Target to $7

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $11.34, a high estimate of $16.00, and a low estimate of $8.00. A decline of 5.03% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746100892_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Teladoc Health among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Grosslight</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.75</td>
<td>$11.00</td>
</tr>
<tr>
<td>Glen Santangelo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$8.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$9.50</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jessica Tassan</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$13.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Teladoc Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Teladoc Health's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Teladoc Health's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Teladoc Health: A Closer Look</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>Teladoc Health: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Challenges: Teladoc Health's revenue growth over 3M faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately -3.03%. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -7.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Teladoc Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -3.23% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For Teladoc Health

Needham analyst Ryan MacDonald reiterates Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) from Hold to Hold.

Needham Reiterates Hold on Teladoc Healthto Hold

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.34) by 44.12 percent. This is a 61.22 percent increase over losses of $(0.49) per share from the same period last year. The company reported quarterly sales of $629.40 million which beat the analyst consensus estimate of $619.29 million by 1.63 percent. This is a 2.59 percent decrease over sales of $646.13 million the same period last year.

Earnings

Earnings Beats

CORRECTION: Teladoc Health Q1 Adj. EPS $(0.19) Beats $(0.34) Estimate, Sales $629.40M Beat $619.29M Estimate

Teladoc Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) reported financial results for the first quarter Wednesday after the bell. Here&#8217;s a rundown<a href="https://www.benzinga.com/pressreleases/25/04/g45116556/teladoc-health-reports-first-quarter-2025-results"> of the report</a>.
Q1 Earnings: Teladoc reported first-quarter revenue of $629.4 million, beating the <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">consensus estimate</a>&nbsp;of $619.29 million, according to <a href="https://benzinga.grsm.io/gxjhpowx7zks" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>. The company reported a first-quarter loss of 53 cents per share, missing analyst estimates for a loss of 34 cents per share.
Total revenue was down 3% on a year-over-year basis. Revenue fell 4% year-over-year in the U.S., but International revenue grew 6% year-over-year. Here&#8217;s a breakdown of revenue by segment:
<ul>
<li>Integrated Care revenue: up 3% to $389.5 million</li>
</ul>
<ul>
<li>BetterHelp&nbsp;revenue: down 11% to $239.9 million</li>
</ul>
<ul>
<li>Access Fees revenue: down 6% to $525.7 million</li>
</ul>
<ul>
<li>Other revenue: up 16% to $103.6 million</li>
</ul>
Cash flow from operations totaled $15.9 million in the quarter. The company said capital expenditures and capitalized software development costs came in at&nbsp;$31.6 million. Teladoc ended the period with approximately $1.19 billion in cash and cash equivalents.
&#8220;We are pleased with the solid start to 2025. Consolidated revenue and adjusted EBITDA were towards the higher end of our&nbsp;first quarter&nbsp;guidance&nbsp;ranges, including our Integrated Care segment being above our ranges for both measures and BetterHelp segment results in the upper half of our ranges as well,&#8221; said&nbsp;Chuck Divita, CEO of Teladoc Health.
&#8220;We also continue to make progress towards strategic priorities aimed at driving sustainable performance, including advancing our position in virtual mental health.&#8221;
In connection with the earnings release, Teladoc also announced that it acquired virtual mental health therapy provider UpLift for $30 million in an <a href="https://www.benzinga.com/pressreleases/25/04/g45116095/teladoc-health-acquires-uplift-expanding-consumer-access-to-mental-health-care-services-through-co">all-cash transaction</a>. The deal also includes up to $15 million in additional contingent earnout consideration.
Guidance:&nbsp;Teladoc expects second-quarter revenue of $614 million to $633 million, and full-year revenue of $2.47 billion to $2.58 billion. Analysts are anticipating full-year revenue of $2.52 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The company also lowered its full-year earnings outlook. Teladoc anticipates a 2025 loss of 90 cents to $1.40 per share, down from prior guidance for a loss of 50 cents to $1.10 per share. Analysts are forecasting a loss of 93 cents per share. 
Teladoc executives are currently discussing the quarter on a call with investors and analysts that got started at 4:30 p.m. ET
TDOC Price Action: <a href="https://www.benzinga.com/quote/TDOC" target="_blank" rel="noreferrer noopener">Teladoc shares</a> were down 5.42% in after-hours, trading at $6.80 at the time of publication on Wednesday, according to <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45115442/sell-in-may-and-go-away-looks-outdated-as-mayjuly-data-signal-bullish-sp-500-seasonality">&#8216;Sell In May And Go Away&#8217; Looks Outdated As May–July Data Signal Bullish S&amp;P 500 Seasonality</a></li>
</ul>
Photo: courtesy of Teladoc Health.

Guidance

Health Care

After-Hours Center

Movers

Teladoc Health Stock Slides On Q1 Earnings As Company Cuts FY25 Guidance

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) lowers FY2025 GAAP EPS guidance from $(1.10)-$(0.50) to $(1.40)-$(0.90) vs $(0.93) analyst estimate. Affirms FY2025 sales outlook from $2.47 billion-$2.58 billion to $2.47 billion-$2.58 billion vs $2.52 billion estimate.

Teladoc Health Lowers FY2025 GAAP EPS Guidance from $(1.10)-$(0.50) to $(1.40)-$(0.90) vs $(0.93) Est; Affirms FY2025 Sales Guidance of $2.47B-$2.58B vs $2.52B Est

Teladoc Health acquired UpLift in an all-cash transaction for $30 million, with up to $15 million in additional contingent earnout consideration. UpLift's 2024 revenue was approximately $15 million. The transaction closed on April 30, 2025, and the results of UpLift will be included in the company's BetterHelp reporting segment going forward.
 &nbsp;

Teladoc Health Acquires UpLift In All-cash Transaction For $30M

AEIS

ALGN

ALKT

AMCR

ANSS

ARAY

ATNI

AWRE

BLCO

BLFY

BLKB

BXMT

CACC

CAKE

CDNA

CFLT

CGNX

CHEF

CHRW

CLMB

CMPR

CNMD

CNXN

COCO

COKE

CPSH

CSLR

CSTM

CTOS

CTSH

CVEO

CWAN

CWEN

DFIN

EBAY

ENVX

EQIX

EQNR

ETSY

EXTR

FCPT

FFWM

FINW

FMBH

FORM

FTAI

GEHC

GKOS

GNRC

GRBK

GRMN

GTES

Earnings Scheduled For April 30, 2025

Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-04-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Teladoc Health will report an earnings per share (EPS) of $-0.37.
Teladoc Health bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 13.56% drop in the share price on the subsequent day.
Here's a look at Teladoc Health's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.29</td>
<td>-0.27</td>
<td>-0.34</td>
<td>-0.46</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.28</td>
<td>-0.19</td>
<td>-0.28</td>
<td>-0.49</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-14.000000000000002%</td>
<td>2.0%</td>
<td>-9.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745949754_0.png" alt="eps graph" />
<h3>Teladoc Health Share Price Analysis</h3>
Shares of Teladoc Health were trading at $7.16 as of April 28. Over the last 52-week period, shares are down 42.78%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Insights Shared by Analysts on Teladoc Health</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teladoc Health.
The consensus rating for Teladoc Health is Neutral, based on 8 analyst ratings. With an average one-year price target of $11.34, there's a potential 58.38% upside.
<h3>Analyzing Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Phreesia, Evolent Health and HealthStream, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Phreesia, with an average 1-year price target of $31.8, suggesting a potential 344.13% upside.</li>
<li>Analysts currently favor an Outperform trajectory for Evolent Health, with an average 1-year price target of $13.75, suggesting a potential 92.04% upside.</li>
<li>Analysts currently favor an Neutral trajectory for HealthStream, with an average 1-year price target of $30.0, suggesting a potential 318.99% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Phreesia, Evolent Health and HealthStream are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teladoc Health</td>
<td>Neutral</td>
<td>-3.03%</td>
<td>$451.56M</td>
<td>-3.23%</td>
</tr>
<tr>
<td>Phreesia</td>
<td>Buy</td>
<td>15.45%</td>
<td>$76.11M</td>
<td>-2.46%</td>
</tr>
<tr>
<td>Evolent Health</td>
<td>Outperform</td>
<td>16.27%</td>
<td>$75.71M</td>
<td>-3.00%</td>
</tr>
<tr>
<td>HealthStream</td>
<td>Neutral</td>
<td>5.18%</td>
<td>$49.12M</td>
<td>1.37%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Teladoc Health ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It also has the lowest Return on Equity among its peers. The company with the highest Revenue Growth and Gross Profit has a Buy rating. The company with the highest Return on Equity has an Outperform rating.
<h3>Delving into Teladoc Health's Background</h3>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>Teladoc Health's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Teladoc Health's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -3.03% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Teladoc Health's net margin is impressive, surpassing industry averages. With a net margin of -7.56%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Teladoc Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.06.
<a href="https://www.benzinga.com/quote/TDOC/earnings">To track all earnings releases for Teladoc Health visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Teladoc Health

Citigroup analyst Daniel Grosslight maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Neutral and lowers the price target from $11 to $8.75.

Citigroup Maintains Neutral on Teladoc Health, Lowers Price Target to $8.75

Jefferies analyst Glen Santangelo maintains Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>) with a Hold and lowers the price target from $10 to $8.

Jefferies Maintains Hold on Teladoc Health, Lowers Price Target to $8

In the preceding three months, 8 analysts have released ratings for Teladoc Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDOC#NYSE">TDOC</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $12.25, a high estimate of $16.00, and a low estimate of $8.00. This current average represents a 1.53% decrease from the previous average price target of $12.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1744372878_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
A comprehensive examination of how financial experts perceive Teladoc Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Lowers &#x7C;Neutral &#x7C; $8.00&#x7C;$9.50 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Lowers &#x7C;Buy &#x7C; $13.00&#x7C;$16.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $12.00&#x7C;$13.00 &#x7C; 
&#x7C;David Roman &#x7C;Goldman Sachs &#x7C;Raises &#x7C;Buy &#x7C; $16.00&#x7C;$14.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $13.50&#x7C;$11.50 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Neutral &#x7C; $11.50&#x7C;$10.50 &#x7C; 
&#x7C;Sean Dodge &#x7C;RBC Capital &#x7C;Raises &#x7C;Outperform &#x7C; $12.00&#x7C;$11.00 &#x7C; 
&#x7C;Michael Wiederhorn &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $12.00&#x7C;$14.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Teladoc Health. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teladoc Health compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Teladoc Health's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Teladoc Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TDOC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teladoc Health analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Teladoc Health</h2>
Teladoc Health Inc is engaged in virtual care, forging a new healthcare experience with Better convenience, outcomes, and value. Its mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience. It operates in Teladoc two segments Health Integrated Care and BetterHelp segments. The majority of its revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems.
<h3>A Deep Dive into Teladoc Health's Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3M period, Teladoc Health faced challenges, resulting in a decline of approximately -3.03% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teladoc Health's net margin excels beyond industry benchmarks, reaching -7.56%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Teladoc Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Teladoc Health's ROA excels beyond industry benchmarks, reaching -1.37%. This signifies efficient management of assets and strong financial health.
Debt Management: Teladoc Health's debt-to-equity ratio is below the industry average at 1.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Press Releases

AI Influence on Medical Diagnostics Generating Billion Dollar Revenues While Growing Adoption Reduces Healthcare Costs

General

Teladoc Health Introduces Next Generation Cardiometabolic Health Program

Teladoc Health to Announce First Quarter 2025 Financial Results

Teladoc Health Acquires UpLift, Expanding Consumer Access to Mental Health Care Services Through Covered Benefits

Teladoc Health Reports First Quarter 2025 Results

Teladoc Health Announces Employee Inducement Awards under NYSE Rule 303A.08

Small Cap

Opinion

Tech That Listens, Learns, and Diagnoses: AI's Breakout Moment in Healthcare

Healthcare Diagnostics Sector Witnessing Significant Growth in Artificial Intelligence Based Technologies

Comments

Teladoc Health

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL